Replies to post #34529 on RespireRx Pharmaceuticals Inc (RSPI)

[alertmeipp]

I think the market is agreeing with you big time. 16 cents right before the SA result - no one really expect nice thing from that thing.

[gfp927z]

Enemem, There's also a chance that CX-1739 will improve SA breathing symptoms, but at the same time will disrupt sleep architecture (as was seen in the CX-717 Sleep Deprivation study, and also in the ADHD trial's relatively high incidence of insomnia). If that happens, then the sleep benefits gained from improved breathing could be negated by the sleep disruption/insomnia effect.

On the positive side though, the SA trial had a tight screening criteria for variability between the 2 baseline night readings (a key reason why it took so long to enroll). The tighter that criteria, the more useful the data will be in showing a drug effect if there is one.